Rolling Stone goes deep on one of the most talked-about questions in medicine: whether the drugs that changed weight loss could change how we respond to the opioid crisis.
The feature follows one woman's experience with GLP-1 support at Caron and puts it next to the growing research effort nationwide. Dr. Adam Scioli explains how Caron's collaboration with Penn State College of Medicine produced one of the first human studies of a GLP-1 for cravings, and what stood out most in the results: the effect showed up at doses lower than those typically used for weight loss.
“A pretty significant reduction in cravings at a much lower dose.”
Levelheaded is an independent company and is not affiliated with or endorsed by Caron Treatment Centers, Penn State, or the outlets referenced. Coverage is shared for informational purposes. GLP-1 medications are not FDA-approved for the uses discussed here, and the research described is early-stage.
